Top Glove Corporation Bhd
SGX:BVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (12.7), the stock would be worth S$0.21 (9% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14 | S$0.23 |
0%
|
| 3-Year Average | 12.7 | S$0.21 |
-9%
|
| 5-Year Average | 5.5 | S$0.09 |
-61%
|
| Industry Average | 12.4 | S$0.2 |
-11%
|
| Country Average | 11.3 | S$0.18 |
-19%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
S$4.6B
|
/ |
Mar 2026
423.1m
|
= |
|
|
S$4.6B
|
/ |
Aug 2026
527.5m
|
= |
|
|
S$4.6B
|
/ |
Aug 2027
600.7m
|
= |
|
|
S$4.6B
|
/ |
Aug 2028
675.5m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| MY |
T
|
Top Glove Corporation Bhd
SGX:BVA
|
5.7B SGD | 14 | 41.3 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62.4B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 28.4 | 39.1 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.1B CHF | 14.5 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
96.5B DKK | 12.9 | 24.3 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.9B USD | 14.8 | 34 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 11.9 | 34.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 16.9 | -15.7 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -83.8 | -37.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
895.2B JPY | 23.2 | 49.1 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 14.5 | 22.6 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 7.2 |
| Median | 11.3 |
| 70th Percentile | 16.9 |
| Max | 56 436.5 |
Other Multiples
Top Glove Corporation Bhd
Glance View
Nestled in the bustling industrial landscape of Malaysia, Top Glove Corporation Bhd has emerged as a pivotal player in the global healthcare supply chain. Founded in 1991 by Tan Sri Dr. Lim Wee Chai, what began as a modest enterprise with a singular production line has transformed into the world's largest manufacturer of gloves. The company’s remarkable journey is powered by its commitment to innovation, stringent quality control, and a relentless drive to expand its production capacity. With operations spanning several countries, Top Glove’s manufacturing capabilities cater to a variety of glove types, including latex, nitrile, and vinyl, addressing the diverse needs of healthcare professionals across the globe. Top Glove operates on a high-volume, low-margin business model, allowing it to thrive in an industry that demands both reliability and cost-effectiveness. The company generates revenue by selling its products to an extensive network of distributors, healthcare institutions, and retailers worldwide. Its strategic approach to cost management and supply chain efficiency enables Top Glove to maintain competitive pricing while ensuring significant profit margins. By continuously investing in technology upgrades and expanding its production facilities, Top Glove ensures it remains at the forefront of the glove manufacturing sector, adeptly navigating the vicissitudes of global health trends and economic cycles.
